Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Brindisi

43 clinical trials in Brindisi, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Brindisi at a glance
43
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

43 trials in Brindisi

Open in trial search

Skin ulcer

Recruiting

Study on the Effectiveness of EscharEx and Amnion/Chorion Membrane Allograft for Patients with Venous Leg Ulcers

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Concentrate of proteolytic enzymes enriched in bromelain
  • Sponsor:Mediwound Ltd.

Cerebral palsy

Recruiting

Study of Cenegermin Nasal Spray for Safety and Tolerability in Children with Spastic Cerebral Palsy

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Ovarian cancer

Recruiting

Study Comparing Rinatabart Sesutecan with Other Treatments for Patients with Platinum-Resistant Ovarian Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Ovarian cancer recurrent

Recruiting

Study of Olaparib for Patients with Recurrent Ovarian Cancer Without BRCA Gene Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Acute myeloid leukaemia

Recruiting

Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Busulfan
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Non-small cell lung cancer stage IV

Recruiting

Study Comparing Atezolizumab Alone and Atezolizumab with Bevacizumab for First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Ricerca Traslazionale

Ovarian cancer

Recruiting

Study on Olaparib for Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Myelodysplastic syndrome

Recruiting

Study of Azacitidine and Drug Combination Before Stem Cell Transplantation in Patients with High-Risk Myelodysplastic Syndrome

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Triple negative breast cancer

Recruiting

Study of Atezolizumab, Vinorelbine, and Cyclophosphamide for Patients with Advanced Triple Negative Breast Cancer Previously Treated with Anti-PD-L1/PD-1

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Acute myeloid leukaemia

Recruiting

Study on Mocravimod for Adults with Acute Myeloid Leukemia Undergoing Stem Cell Transplant

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mocravimod
  • Sponsor:Priothera S.A.S.

Breast cancer metastatic

Recruiting

Study of Palbociclib and Fulvestrant for Women with Advanced Breast Cancer After Previous CDK4/6 Inhibitor and Hormonal Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:Consorzio Oncotech

Small cell lung cancer extensive stage

Recruiting

Study on Durvalumab with Carboplatin or Cisplatin and Etoposide for First-Line Treatment in Patients with Extensive Stage Extrapulmonary Small Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Brindisi

What the registry says about research in the country

01 Hematologic Oncology

Innovative clinical trials focusing on Acute Myeloid Leukemia and Follicular Lymphoma, investigating new therapeutic approaches including targeted treatments and immunotherapy combinations.

  • Gemtuzumab Ozogamicin therapy evaluation
  • Shortened chemotherapy with immunotherapy
  • Mocravimod in transplant patients

Research aims to improve treatment outcomes and patient survival rates through personalized therapeutic strategies.

02 Breast Cancer Research

Comprehensive studies on various types of breast cancer, particularly focusing on hormone receptor-positive and HER2-positive disease variants.

  • Hormone therapy optimization
  • Novel drug combinations
  • Treatment sequencing strategies

Investigations aim to enhance treatment efficacy through targeted therapies and precision medicine approaches.

03 Gynecologic Oncology

Advanced research in ovarian cancer and related conditions, with particular emphasis on maintenance therapies and biomarker-driven treatment approaches.

  • BRCA-related studies
  • Maintenance therapy evaluation
  • Novel combination treatments

Studies focus on improving progression-free survival and identifying effective treatment strategies.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.